{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-038041","form_type":"8-K","ticker":"KNSA","cik":"0001730430","company_name":"Kiniksa Pharmaceuticals International, plc","filed_at":"2025-04-23T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.503193+00:00","generated_at":"2026-05-23T08:18:15.250523+00:00","sec_items":["5.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Kiniksa approves KPL-387 LTIP for execs, grants PSUs and options tied to BLA submission and FDA approval","bullets":["Compensation Committee approved KPL-387 Long-Term Incentive Plan for executive officers, linked to BLA submission (Milestone 1) and FDA approval (Milestone 2) for recurrent pericarditis treatment.","CEO Sanj Patel granted 16,312 PSUs and 26,142 options; CFO Mark Ragosa granted 9,309 PSUs and 14,918 options.","Awards include cash, PSUs, and options, with earnout percentages (100%, 75%, 50%, 0%) based on milestone achievement dates.","If a change in control occurs, unvested awards may accelerate under specified conditions, including termination without cause or resignation for good reason.","The plan covers five named executive officers; cash award amounts are based on base salary at milestone achievement."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-038041","json":"https://secwatch.observer/filing/0001104659-25-038041.json","markdown":"https://secwatch.observer/filing/0001104659-25-038041.md","text":"https://secwatch.observer/filing/0001104659-25-038041.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1730430/000110465925038041/0001104659-25-038041-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1730430/000110465925038041/tm2512708d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T08:18:15.250523+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}